Suppr超能文献

前列腺特异性抗原在前列腺切除术后生化复发的挽救性放疗后预测长期结果,包括总生存。

Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.

机构信息

a Department of Radiation Oncology , University Hospital Ulm , Germany.

b Department of Radiation Oncology , Esslingen Hospital , Germany.

出版信息

Acta Oncol. 2018 Mar;57(3):362-367. doi: 10.1080/0284186X.2017.1364869. Epub 2017 Aug 17.

Abstract

BACKGROUND

For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% of the patients experience further progression. With a focus on the pre- and post-SRT serum level of the prostate-specific antigen (PSA), we assessed the determinants of the long-term outcome after SRT.

PATIENT AND METHODS

Between 1997 and 2011, 464 patients received 3D-conformal SRT with median 66.6 Gy. The median PSA level before SRT was 0.31 ng/ml. In our retrospective analysis, post-SRT progression was defined as either a rising PSA >0.2 ng/ml above the nadir, or the application of anti-androgens or clinical recurrence. A PSA <0.1 ng/ml was termed undetectable. We analyzed the data with the Kaplan-Meier method (Logrank test) and multivariable Cox regression.

RESULTS

The median follow-up was 5.9 years. Overall, 178 patients had recurrence, 13 developed distant metastases and 30 died. Univariate, a pre-RP PSA <10 ng/ml, pathological stage pT <3, Gleason score <8, positive surgical margins, a pre-SRT PSA <0.2 ng/ml and a post-SRT PSA nadir <0.1 ng/ml correlated with fewer and later second recurrences. In a multivariable Cox model, pT, Gleason score, margin status and pre-SRT PSA were significant covariates of progression. If the post-SRT PSA response was included in the regression analysis, then a nadir ≥0.1 ng/ml was the strongest risk factor. Initiating SRT at a PSA <0.2 ng/ml correlated with a post-SRT PSA <0.1 ng/ml. Men who achieved an undetectable post-SRT PSA nadir also had lower rates of metastases and a better overall survival. However, there were too few events for Cox regression analysis of these two endpoints.

CONCLUSIONS

Early SRT at a PSA <0.2 ng/ml correlates with re-achieving an undetectable PSA, which predicts improved freedom from progression and metastases and better overall survival.

摘要

背景

对于根治性前列腺切除术(RP)后复发的前列腺癌患者,挽救性放疗(SRT)是治愈的第二次机会。然而,根据风险因素,40-70%的患者会出现进一步进展。我们关注 SRT 前后前列腺特异性抗原(PSA)的血清水平,评估了 SRT 后长期结果的决定因素。

患者和方法

1997 年至 2011 年间,464 例患者接受了中位剂量为 66.6Gy 的 3D 适形 SRT。SRT 前 PSA 中位数为 0.31ng/ml。在我们的回顾性分析中,SRT 后进展定义为 PSA 升高>0.2ng/ml 以上且高于最低点,或应用抗雄激素或临床复发。PSA<0.1ng/ml 称为不可检测。我们使用 Kaplan-Meier 方法(Logrank 检验)和多变量 Cox 回归分析数据。

结果

中位随访时间为 5.9 年。总的来说,178 例患者复发,13 例出现远处转移,30 例死亡。单因素分析显示,RP 前 PSA<10ng/ml、病理分期 pT<3、Gleason 评分<8、切缘阳性、SRT 前 PSA<0.2ng/ml 和 SRT 后 PSA 最低点<0.1ng/ml 与复发次数减少和复发时间延迟相关。在多变量 Cox 模型中,pT、Gleason 评分、切缘状态和 SRT 前 PSA 是进展的显著协变量。如果将 SRT 后 PSA 反应纳入回归分析,则最低点≥0.1ng/ml 是最强的危险因素。SRT 开始时 PSA<0.2ng/ml 与 SRT 后 PSA<0.1ng/ml 相关。达到 SRT 后 PSA 最低点不可检测的患者转移率也较低,总生存率较好。然而,这两个终点的 Cox 回归分析事件太少。

结论

SRT 早期在 PSA<0.2ng/ml 时与再次达到 PSA 不可检测相关,这预测了无进展和转移的改善以及更好的总生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验